Anthracycline Cardiotoxicity Biobank and Registry

Characterization of TRPC6 to Predict and Prevent Chemotherapy-Related Cardiomyopathy and Heart Failure in Women

This United States Department of Defense-funded study enrolls patients who have developed cardio-toxicity from anthracycline chemotherapy such as doxorubicin for their cancer treatment in order to understand how genetic variants can influence the development of cardiomyopathy. This study involves one blood draw at the time of enrollment and the collection of clinical data from the electronic medical record.

Please contact our Clinical Trials Office for information: 352.273.8933